Workflow
上海医药(601607) - 2014 Q1 - 季度财报

Financial Performance - The company achieved operating revenue of RMB 21.27 billion in Q1 2014, representing a year-on-year growth of 8.60%[12] - The net profit attributable to shareholders was RMB 586.23 million, a decrease of 6.30% compared to the same period last year[12] - The pharmaceutical manufacturing segment generated revenue of RMB 2.82 billion, with a gross margin of 46.33%[12] - The pharmaceutical distribution business reported revenue of RMB 18.50 billion, up 8.96% year-on-year, with a gross margin of 6.30%[12] - The retail pharmacy business achieved revenue of RMB 804 million, reflecting a growth of 19.63% year-on-year, with a gross margin of 20.41%[12] - Total operating revenue for the current period reached ¥21,274,115,894.43, an increase of 8.6% compared to ¥19,590,198,049.21 in the previous period[32] - Total operating costs amounted to ¥20,508,912,370.34, up 8.8% from ¥18,850,976,956.70 in the prior period[32] - Operating profit decreased to ¥850,934,969.54, down 3.9% from ¥885,915,212.91 year-over-year[32] - Net profit for the current period was ¥678,536,030.20, a decline of 7.9% compared to ¥736,830,239.81 in the previous period[32] - Basic earnings per share decreased to ¥0.2180 from ¥0.2327, reflecting a 6.1% decline[33] - Comprehensive income totalled ¥659,516,055.13, down 10.6% from ¥737,583,917.56 in the previous period[33] Cash Flow - The net cash flow from operating activities was negative RMB 564.59 million, a decline of 118.98% year-on-year[10] - Cash inflow from operating activities increased to ¥23,127,148,427.31, compared to ¥20,228,552,301.98 in the prior period[38] - Cash outflow from operating activities rose to ¥23,691,739,174.13, up from ¥20,486,378,547.91 year-over-year[39] - The net cash flow from operating activities was negative at ¥564,590,746.82, worsening from a negative ¥257,826,245.93 in the previous period[39] - The company reported a cash inflow of 522,792,428.36 RMB from investment activities, with 351,058,750.00 RMB received from other investment-related cash[43] - The net increase in cash and cash equivalents was -563,971,404.40 RMB, compared to -606,857,569.45 RMB in the previous period[41] Assets and Liabilities - The company’s total assets increased by 3.42% to RMB 58.24 billion compared to the end of the previous year[10] - The net assets attributable to shareholders rose by 1.91% to RMB 26.45 billion[10] - Total current assets increased from RMB 42,514,973,082.06 to RMB 44,394,967,503.37, reflecting a growth in inventory and accounts receivable[22] - Current liabilities increased to CNY 28.67 billion from CNY 27.31 billion, reflecting a growth of approximately 5%[25] - Accounts payable increased to CNY 15.26 billion, up from CNY 14.15 billion, marking a rise of about 7.8%[24] - The total owner's equity reached CNY 29.56 billion, compared to CNY 29.00 billion, showing an increase of approximately 1.9%[25] - The total liabilities increased to CNY 28.67 billion, up from CNY 27.31 billion, indicating a growth of about 5%[25] Shareholder Information - Total number of shareholders is 97,223 for A shares and 3,110 for H shares[15] - The top ten shareholders hold a total of 1,200,000,000 shares, with HKSCC NOMINEES LIMITED holding 27.83% and Shanghai Pharmaceutical Group holding 26.65%[15] Management and Legal Issues - The company is actively responding to a lawsuit regarding unfair competition involving its subsidiary, indicating ongoing legal challenges[18] - The company’s vice president has resigned, with no reported disagreements with the board, reflecting potential changes in management[19] - The company has committed to maintaining transparency regarding shareholder commitments and related announcements[20] Financial Expenses and Investment Income - Financial expenses increased by 213.40% from RMB 32,243,253.75 to RMB 101,050,153.19 due to rising borrowing rates and reduced funding returns[19] - Investment income decreased by 41.57% from RMB 146,723,795.40 to RMB 85,725,855.25 due to reduced investment income from joint ventures[19]